Micro-Dose Calibrator for Pre-clinical Radiotracer Assays


Molecular imaging is a disease-specific targeting modality that promises much more accurate diagnoses of serious diseases such as cancer and infections. Agents are being continually developed with a view to clinical translation, with several such therapies requiring measurement of very small doses. Currently, there is no way of accurately measuring small amounts of radioactivity used in many pre-clinical tracer studies, as on-the-market commercial dose calibrators measure at too high a dose range, typically at 10-1000 µCi and higher. Using such commercial calibrators to estimate micro-doses (0.01-10 µCi) results in unavoidable and up to ± 20% measurement errors. Alternatively, well-counters that can measure small doses are not suited for measurements of doses greater than 1 µCi, resulting in a coverage gap (1-10 µCi), a critical range for bio-distribution studies, cell binding studies, immune cell labeling techniques, and α-based therapies.

To solve the problem of measuring a wider range of radioactivity doses, and without the need of a volumetric correction, the NCI Molecular Imaging Program invented a device (see images below) that can accurately measure radioactivity doses between 0.1-100 µCi,  with 1% error. The device is a working prototype and requires collaboration to manufacture it. NCI seeks parties to commercialize this technology through collaborative co-development or licensing.

Video abstract: New and improved micro dose-calibrator designed to accurately measure radioactive doses in the range of 50 nCi to 100 µCi with 99% precision, useful in radio-ligand bio-distribution studies, cell binding studies, immune cell labeling techniques, and α-based therapies.

 An improved device for accurately measuring the injectable dose of small amounts of radioactivity used in many pre-clinical tracer studies.  The improved device can accurately measure radioactivity doses between 0.1-100 μCi with 1% error.  It also replaces the need for two less accurate commercially available devices; one covering the low end of the measurement range and the other covering the high end of the range.



Potential Commercial Applications: Competitive Advantages:
  • Bio-distribution pre-clinical studies Immune cell cancer therapy
 
  • Measure small doses between 50 nCi (1.8 kBq) and 100 µCi (3.7 MBq) with 1% accuracy
  • Measure volumes of activity up to 20cc without volumetric correction to 1% accuracy


Development Stage:
Prototype

Inventors:

Stephen Adler (FNLCR)  ➽ more inventions...


Intellectual Property:
Application No. 62/554,980

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-241-2016
Updated: Jul 27, 2019